Objective To determine whether multiple daily injections of parathyroid hormone (PTH) 1-34 are safe and effective as long-term therapy for children with hypoparathyroidism.
H ypoparathyroidism remains among the few classic hormonal insufficiency states for which replacement therapy remains widely unavailable. [1] [2] [3] Although conventional calcitriol and calcium treatment can maintain normal serum calcium, this therapy entails multiple daily pills of calcitriol, calcium, and/or magnesium, and may produce nephrocalcinosis and impair renal function. 4, 5 These renal complications arise because calcitriol lacks parathyroid hormone's renal calcium-retaining effects and maintains serum calcium principally by increasing gastrointestinal calcium absorption. [6] [7] [8] To avoid hypercalciuriainduced renal damage, calcitriol dosage must be adjusted to maintain serum calcium at the lowest tolerated level. Hypocalcemia, however, may lead to tetany, laryngospasm, seizures, and potential brain injury, and thus conventional management involves a delicate balance between hypercalciuria and hypocalcemia.
Genetic etiologies of hypoparathyroidism pose unique treatment challenges that, in many cases, cannot be overcome with conventional therapy. Patients with autoimmune polyglandular syndrome type 1 (APS-1), also called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, may have intermittent malabsorption causing an inability to absorb conventional therapy. 9, 10 Patients with an activating calcium receptor mutation (CaR) exhibit excessive urine calcium even when serum calcium is low and, thus, do not respond well to conventional therapy.
Parathyroid hormone (PTH) 1-34 treatment in adults with CaR, when given once daily, failed to normalize urine calcium excretion, whereas twice-daily injections provided improved, albeit still abnormal, calcium homeostasis. 5 Similar results were observed in a randomized controlled study in children. 12 A subsequent study showed safe and effective treatment with twicedaily PTH 1-34 for up to 3 years-with normal linear growth, weight gain, and bone accretion, and high-normal or just above normal bone turnover markers in children. 13 Randomized studies comparing pump delivery of PTH 1-34 with twice-daily injections in adults 14 and children 15 showed normal serum and urine calcium and bone turnover markers with pump delivery. Pump delivery seemed particularly promising for future long-term study in children with APS-1 or CaR, in whom concurrent normalization of serum and urine calcium has been difficult to achieve. These and other studies showed that patients with congenital hypoparathyroidism require larger PTH 1-34 dosage (expressed as mcg/kg/day) than patients with postsurgical hypoparathyroidism. 5, 14, 15 In each study, however, PTH 1-34 daily dose requirement decreased as dose frequency was increased from once daily to twice daily to pump delivery.
Long-term PTH treatment studies in adults with hypoparathyroidism, treated with twice-daily PTH 1-34 for 3 years 16 or with alternate-day PTH 1-84 plus concurrent conventional therapy for 6 years, 17 have shown normal or slightly below normal serum calcium levels with persistently elevated bone turnover markers.
The current report presents results over a prolonged duration of PTH 1-34 replacement therapy in children with hypoparathyroidism-data that are essential because the need for therapy is life-long, PTH 1-34 may have long-term effects on bone accrual, and the assessment of any adverse impact on renal function may take many years to confirm. In this report, we describe linear growth, bone accrual rates, mineral homeostasis, and renal function (observed longitudinally for up to 10 years) in 14 PTH 1-34-treated children with hypoparathyroidism attributable to APS-1 or CaR.
Methods
This institutional review board-approved observational study was conducted at the National Institutes of Health (NIH), Clinical Center, Bethesda, Maryland. All participants had hypoparathyroidism because of APS-1 or an activating CaR mutation and were treated with synthetic human PTH 1-34 as previously described. 6 Mutational analysis was performed in commercial laboratories (Gene DX [Gaithersburg, Maryland], Athena Diagnostics [Marlborough, Massachusetts]), except for patients A, C, and I, whose mutations were identified at NIH Clinical Center (Table I) . Renal computed tomography (CT) and ultrasound (US) scans were rated by 2 radiologists from the NIH Clinical Center who reviewed and graded all scans independently and then together reviewed a subset of scans a third time to resolve inconsistencies. The following levels of calcifications were attributed to each scan according to methods previously described 18, 19 : 0, no calcifications; 1, mild, 2, moderate, and 3, severe nephrocalcinosis. Repeated renal imaging was not included prospectively in the study protocol, but results of repeat renal imaging were analyzed for the 12 subjects in whom they were available. Imaging results for cerebral calcifications were also analyzed when available.
At study initiation, subjects had a 1-week inpatient stay for baseline evaluation, discontinuation of conventional therapy, and start of twice-daily PTH 1-34 injections. Follow-up outpatient evaluations, performed semiannually, included review of interim history, a physical examination, and repeat of the pre-PTH baseline studies, including height (mean of 3 Harpenden Stadiometer [Holtain, Crymych, Great Britain] measurements), bone density by dual energy x-ray absorptiometry (DXA), and 3 days of morning blood (pre-PTH injection) and 24-hour urine collection for mineral levels (calcium, phosphate, and magnesium) and measurement of bone turnover markers (serum alkaline phosphatase, urine pyridinoline and deoxypyridinoline). Measurements were performed at NIH Clinical Center or Mayo Medical Labs, Rochester, Minnesota as previously described. 15 Between NIH visits, blood and urine mineral levels were measured monthly by the patient's local physician, with results sent to the study PI for PTH 1-34 dose adjustment as needed.
Height Z-scores were determined according to Centers for Disease Control and Prevention reference data. 20 Adult height criterion was bone age ≥16 in boys or ≥15 in girls and height velocity ≤2 cm/year. Bone mineral density of the lumbar spine, radius, hip and whole body were measured on a QDR 4500 scanner (Hologic, Inc, Bedford, Massachusetts). Bone density and content Z-scores, and bone-accrual velocity and heightvelocity Z-scores were determined from Bone Mineral Density in Childhood Study standards, and height adjustment was applied to all Z-score results.
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Statistical Analyses
Sex-and pubertal status-specific bone mineral content (BMC) and areal bone mineral density (aBMD) velocity Z-scores, adjusted for baseline age, height, weight, BMC/aBMD, and interval weight and height velocity, were generated from the Bone Mineral Density in Childhood Study 21, 22 ; prediction equations were based upon generalized mixed-effects models with an independent correlation structure (submitted for publication). Height velocity Z-scores were based on age, sex, and pubertal timing specific reference ranges. 23 Differences between PTH-treated patients with hypoparathyroid and Bone Mineral Density in Childhood Study reference standards, in height velocity Z-score and in BMC and aBMD velocity Z-scores for each yearly interval, were assessed using generalized estimating equations with independent correlation structure. Patients A and I were not included in these bone mineral accretion analyses because most of their DXA scans were performed using the Hologic 2000 scanner (Hologic, Inc, Bedford, Massachusetts).
Longitudinal trajectories for each outcome measure were estimated using the linear mixed model approach, which can account for both the mean trajectories (estimated fixed effects) and individual trajectories (addition of fixed and individual patient's random effects). Time of study was divided into 2 intervals-baseline to 1 year and >1 to 10 years. A dosage fixed effect accounted for varying PTH 1-34 dosage. A diagnostic subgroup effect accounted for potential differences between APS-1 and CaR. Urine excretion values were adjusted to body surface area of 1.73 m 2 . Between-group APS-1 vs CaR distributional differences (testing mean differences) in the calciumphosphate product (Ca × P), and in serum and urine calcium levels, were analyzed by 2-sample t test.
Results
The subjects were 14 children with severe hypoparathyroidism ( Table I) . Except for patient I, who was receiving 1-alpha calcidiol at baseline, all were receiving calcium and calcitriol at study entry.
Five patients had APS-1 (ages 7-12 years; 1 male) and 9 had CaR (ages 7-16 years; 4 male). Among patients with APS-1, patients A, B, and D had the common autoimmune regulator (AIRE) gene mutation c.967_979del13, and patients A and E had the R257X mutation. Patients B and E were homozygous for AIRE mutations, and patients A and D, who had a novel mutation, 24 were compound heterozygotes. AIRE mutations were not detected in patient C, who had hypoparathyroidism and Addison disease, as did an older brother. Sequencing included AIRE exomes, flanking intron-exon regions, and copy number variation to identify deletions not found by Sanger sequencing. 10 Among patients with CaR, all had activating mutations, which were novel in F, I, J, and N. Hypoparathyroidism was diagnosed at age 2-5 years in all patients with APS-1, and in infancy in all patients with CaR except J and N. Patients K and L are brothers. Before medical diagnosis, hypoparathyroidism was accompanied by tetany (A, B, C, and I) and/or seizures (A, B, D, E, I, J, M, and N) for extended periods.
At study baseline, all patients had normal renal function and all who had renal imaging (B-N), had nephrocalcinosis. Patient I was diagnosed with nephrocalcinosis by US prior to study entry. Greater height deficits were observed in patients with APS-1 vs CaR (P < .04). Patients B, C, D, G, and H had a history of poor linear growth, with B, G, and H having height Z-scores <-1.5. At baseline visit, patient C was diagnosed with growth hormone deficiency and treated with growth hormone. All patients except A had chronic magnesium deficiency.
After baseline evaluation, patients A and I participated in a 6-month randomized crossover study 12 comparing once-aday and twice-daily PTH 1-34. The sequence for patient A was once-a-day/twice-daily PTH and for patient I was twicedaily/once-daily PTH. This dose study was followed by a 3-year randomized, parallel NIH study comparing twicedaily PTH 1-34 with calcitriol plus calcium. 13 They (A and I) received twice-daily PTH 1-34 injections for 3 years before continuing twice-daily therapy in this observational study.
Data for current analysis ended when participants reached age 21 years (patients A and C), discontinued the study (patient I: after 6.5 years), or were discharged from the study at its conclusion (patients B, D-H, and J-N). Subsequently, most patients have continued receiving PTH 1-34 as rhPTH1-34 (teriparatide, Forteo, approved for osteoporosis treatment).
PTH Therapy
Twice-daily subcutaneous PTH 1-34 injections were begun at the dose of 0.5 µg/kg body weight/day. Magnesium supplements were continued as needed to correct hypomagnesemia. Calcium supplements were discontinued, but permitted emergently for tetany, except for patient N who was given 300 mg elemental calcium carbonate with meals because of milk protein allergy and low dietary calcium.
Four patients with CaR and patient B with APS-1, received thrice-daily PTH 1-34 during some or all of the study. Thrice-daily treatment began at baseline in patient B, at study year 0.5 in patients K and N, at year 2 in L, and at year 6.5 in H. Twice daily PTH injections led to bone pain in patient K, which disappeared with smaller PTH doses given thrice daily. Patient B, a 9-year-old child with APS-1, including Addison disease, hypoparathyroidism, malabsorption, nephrocalcinosis, and lithiasis had a history of multiple hospitalizations for hypocalcemia, asthma, and adrenal insufficiency. The purpose of thrice daily was hypothetically to provide a more a physiologic approach to therapy by decreasing the total daily dose and potentially to lower urine calcium excretion and reduce serum calcium fluctuation. In patient H, with the most data on each regimen, twice-daily PTH 1-34 (0.5-6 years) vs thricedaily (6.5-10 years) reduced mean PTH 1-34 dose from 40.2 µg/ day (1.4 µg/kg/day) to 19.5 µg/day (0.54 µg/kg/day, P < .0003), reduced serum calcium, magnesium, and alkaline phosphatase (from 224 to 154 U/L) and 24-hour urine magnesium (data not shown, all P < .01), without significant change in 24-hour urine calcium (8.7 to 7.7 mmol/24 hour).
Mean PTH 1-34 dose was 0.35 ± 0.08 µg/kg/dose or 0.75 ± 0.15 µg/kg/day. PTH dose range per injection was 4-54 µg (0.1-0.75 µg/kg/injection), with daily total 8-108 µg (0.2-1.49 µg/kg/day), given subcutaneously twice or thrice daily. Mean dose did not differ according to diagnostic group. Individual PTH 1-34 dose requirements appeared to be influenced by severity of hypoparathyroidism for patients with APS-1, and by functional severity of CaR mutation for the patients with CaR. Mean PTH 1-34 treatment duration was 6.9 ± 3.1 y (range: 1.5 -10 y).
PTH 1-34 dose was adjusted to the lowest urine calcium level that could be achieved without symptomatic hypocalcemia, which resulted in serum calcium levels at the lower normal or slightly below normal range. Injection sites included arm, thigh, or abdomen, depending on patient preference, with instruction to rotate sites. During initial inpatient dose adjustment, serum and urine calcium were measured daily or twice daily. Thereafter, outpatient monitoring frequency was reduced progressively to monthly, if feasible. However, hypo-or hypercalcemia episodes often prompted more frequent blood calcium monitoring.
Participation in this long-term observational study was interrupted for 6 months in 9 patients (between study year 0.5-1 in patient F and study years 4-10 in patients B, C, E, G, H, K, THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 203 L, and M) to take part in a 6-month randomized, crossover study comparing PTH 1-34 delivery by pump vs twice-daily injection. 15 The current analyses excluded data from these 3 months of PTH 1-34 pump delivery.
Linear Growth and Bone Mineral Accrual
Patients with APS-1 and CaR did not differ significantly in linear growth or bone mineral accrual Z-scores during PTH 1-34 treatment, and data for these outcomes have been combined for presentation (Figure 1) . Mean height velocity was normal for age throughout the study.
All patients except B, I, and J reached adult height during PTH 1-34 treatment, and patients B and I attained adult height (measured at NIH) while receiving rhPTH1-34 (Forteo) after study conclusion. Patient J had not attained adult height at time of report. APS-1 patients B, C, and D were 8-12 cm below their sex-adjusted midparental height (MPH) at adult height. By contrast, all patients with CaR except G attained MPH, and patients H and M exceeded MPH by 4 and 6 cm, respectively.
Lumbar spine, whole body, and femoral neck bone accretion velocities remained normal throughout treatment. In study years 1 and 2, bone mineral density accrual velocity at the distal one-third radius was reduced vs age-matched reference values (one-third radius aBMD velocity Z, Figure 1 , P < .05) but normalized in years 3-5. During study years 2 and 4, total hip bone accrual Z-scores were greater than average (P < .01).
Bone Turnover Markers and Vitamin D Mean ± SD serum alkaline phosphatase remained normal (235.31 ± 104.758 U/L, N: 51-332 U/L). Urine pyridinoline and deoxypyridinoline did not change significantly during treatment (494.6 ± 237.4 and 209.9 ± 99.5 nmol/mmol creatinine, respectively). All 3 bone markers correlated with the PTH 1-34 dose (P < .003), and there was no diagnostic group effect. Mean ± SD 1,25-dihydroxyvitamin D3 (63.5 ± 8.4 pg/mL, N: 24-86 pg/mL) and 25-hydroxyvitamin D3 (38 ± 7.1 ng/mL, N: 25-80 ng/mL) levels remained normal without significant change during treatment and both were significantly higher in APS-1 vs CaR (P < .02; Table II [available at www.jpeds.com]). Mean 25-hydroxyvitamin D3 was inversely related to PTH dose (P < .05).
Serum and Urine Mineral Levels
Serum and 24-hour urine calcium correlated with the PTH 1-34 dose (P < .001). Mean ± SD serum and 24-hour urine calcium levels during treatment were 2.05 ± 0.11 mmol/L (N: 2.05-2.5 mmol/L) and 6.93 ± 1.3 mmol/d (N: 1.25-7.5 mmol/ d), respectively. Mean serum calcium decreased significantly from study baseline to 1 year (−0.13 mmol/L, P < .04), as did urine calcium (-1.6 mmol/d, P < .03), and did not change significantly thereafter (>1-10 year).
During calcitriol and calcium treatment at study baseline, analysis of the distribution of serum and urine calcium showed more frequent low, and fewer normal, serum calcium levels in CaR vs APS-1, with only minor differences in the frequency of elevated urine calcium levels between diagnostic groups (Figure 2, A) . PTH 1-34 treatment (0.5-10 y) produced fewer normal or high, and more low, serum calcium levels (P < .001), with less frequent hypercalciuria (from 58% to 24% of measurements for APS-1 and from 61% to 52% for CaR) and more frequent normal urine calcium (Figure 2 , B, P < .001).
Mean serum phosphate and magnesium levels decreased significantly during PTH 1-34, with most of the decrease occurring after year 1 (data not shown, P < .01). Serum phosphate levels were related inversely to PTH 1-34 dose (P < .01), with no diagnostic group effect. By contrast, urine phosphate and serum and urine magnesium levels were not related to PTH 1-34 dose, and urine phosphate and magnesium did not change significantly during treatment.
APS-1 vs CaR Serum and Urine Mineral Levels
Serum calcium and magnesium were significantly higher, and serum phosphate significantly lower, for APS-1 vs CaR patients; mean ± SD serum calcium, 2.08 ± 0.18 and 1.95 ± 0.22 mmol/L, respectively (P < .0001); serum magnesium, 0.72 ± 0.07 and 0.65 ± 0.14 mmol/L (P < .0001); and serum phosphate, 1.55 ± 0.35 and 1.69 ± 0.36 mmol/L (P < .02). Correspondingly, urine calcium, magnesium and phosphate were significantly lower for patients with APS-1 vs CaR (all P < .001; Table II)
Calcium-Phosphorus Product
The product of the serum calcium and phosphorus concentrations is referred to as the calcium-phosphorus product (Ca × P). Mean Ca × P was 41 ± 8, and 93% of determinations were <55 mg )-a threshold used in managing adults with hypoparathyroid to lower the risk of renal calcification. 25, 26 However, Ca × P did not correlate with 24-hour calcium excretion, and high 24-hour urine calcium values were observed with both high and low Ca × P values ( Table III) . The distribution of Ca × P values was skewed toward higher levels for patients with CaR vs APS-1, which produced higher mean Ca × P in the CaR group (42 ± 7 vs 39 ± 9; P < .02, Figure 3 [available at www.jpeds.com]). 
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Creatinine Clearance Mean ± SD creatinine clearance, corrected for body surface area (102.63 ± 23.15 mL/min/1.73 m 2 ), showed no significant change over time, and no dose or diagnostic group effect.
Nephrocalcinosis
Seven patients with CaR (G, H, I, K, L, M, and N) had renal US showing nephrocalcinosis before study entry, between ages 1.3 and 5 years for all patients except L (8 years of age) and G (12 years of age). At study baseline, kidney CT in 8 patients with CaR (G-N) showed nephrocalcinosis in all except patient I whose baseline CT scan was missing and not available for this analysis. She was diagnosed with nephrocalcinosis by US 2 years prior to protocol entry by her local nephrologist. Patient F with CaR had renal US at baseline showing moderate nephrocalcinosis. CT scans at baseline in patients with APS-1 B-E showed mild nephrocalcinosis.
Repeat renal imaging in 12 patients showed progression of nephrocalcinosis in 5 patients (3 CaR and 2 APS-1). Patients with APS-1 C and E showed no progression at study year 8.5 and 9.5, respectively, and patients B and D progressed to moderate nephrocalcinosis at years 4 and 9, respectively. CaR patients H and K, with moderate nephrocalcinosis at baseline, had severe nephrocalcinosis at year 6 and 3.5, respectively. Patient M with mild nephrocalcinosis progressed to moderate at year 4.5 years. By contrast, CaR patients F, G, J, L, and N showed no progression of renal calcifications. Patient G, with moderate nephrocalcinosis (at 0, 1, 3, and 5 years) by CT or US, had a pattern of mild nephrocalcinosis on US at study year 6. Four patients had nephrolithiasis diagnosed at baseline (B and F) or prior to study entry (E and H). Patients C, G, H, K, and N had nephrolithiasis seen on US between study years 4-10.
Both renal CT and US imaging were performed during this study; concurrent CT and US in patients H (baseline) and K (3.5 years) revealed moderate nephrocalcinosis by CT but severe nephrocalcinosis by US. Concurrent CT and US in patient M at study year 4.5 revealed severe nephrocalcinosis by CT and moderate nephrocalcinosis by US.
Cerebral Calcifications
Patient B, with normal baseline brain CT, showed a small calcification in the left globus pallidus at year 4. Patient M, who had evidence of brain calcifications from early childhood, had repeat brain scans (at study years 1 and 4) showing similar calcifications in basal ganglia and thalami. Other patients had brain CT scans at various time points throughout the study. Only patients E and F had no evidence of calcifications. (Table IV ; available at www.jpeds.com) Adverse Events Related to APS-1 APS-1 is characterized by at least 2 of the following major criteria: chronic mucocutaneous candidiasis, adrenal insufficiency, and hypoparathyroidism. 9, 10 Patients A, B, and D had chronic fungal infections diagnosed between 6-24 months. Patients A through E had Addison disease and malabsorption, which were diagnosed between ages 5 to 13 years. Patients C and D had poor weight gain associated with intermittent malabsorption during study years 3 and 9, respectively. Patient D required total parenteral nutrition and a feeding tube during study years 9-10. Patients A and E were diagnosed with ovarian failure (elevated follicle stimulating hormone) at ages 11 and 10 years, respectively. Both were placed on estradiol to initiate breast development and later placed on hormonal replacement therapy by pills or patch. Patient B had reactive-airway disease, diagnosed at age 3 years. CT imaging of the chest for evidence of autoimmune pneumonitis was negative at age 9 years. Patient C, who had failure to thrive and malabsorption, received 5 years of GH treatment for growth hormone deficiency beginning at study entry. Patient C also had pubertal delay with a 2-to 3-year bone age delay, and received monthly testosterone injections from age 14 years until onset of puberty at age 17 years. Three patients (B, D, and E) had biopsy proven chronic active hepatitis, diagnosed at 8, 10, and 4 years old, respectively.
In patients with intermittent malabsorption, therapies that bypass the gastrointestinal tract were used to manage endocrinopathies. Pubertal initiation in patients A and E was done with a low-dose transdermal estrogen and, in patient C, with intramuscular testosterone. Vitamin D deficiency was treated with intramuscular vitamin D. Addison disease was treated with thrice-daily oral steroid doses at a higher dose (15 mg/m 2 ) than typically required for physiologic replacement.
The inclusion of regular screening for autoantibodies helped us to identify a higher risk of autoimmune diseases associated with APS-1. We relied on classic hormonal testing to diagnose Addison disease, gonadal failure, or thyroiditis. Patient D had a positive adrenal antibody panel at age 4 years and was diagnosed with Addison disease at age 11 years. Patients C and D had positive thyroid antibodies when thyroiditis was diagnosed. Patient A had elevated thyroglobulin antibodies at age 17 years with no other biochemical evidence of thyroid disease.
Adverse Events
No study-related serious adverse events occurred during the study. Patient K developed tibial bone pain when given PTH 1-34 twice daily which resolved with thrice daily PTH 1-34. Patients A, C, E, and M experienced recurrent headaches and A, C, and D complained of muscle weakness. Patient L suffered a finger fracture while playing basketball during the first year of PTH 1-34 therapy. Patients B and I had asthma which was exacerbated by upper respiratory infections and exercise. Ca × P was measured in morning serum samples before PTH dose. Range and mean ± SD of urine calcium excretion were determined from the corresponding 24-hour urine calcium collections.
Enamel hypoplasia was observed in all patients (A-N) at study baseline.
Quality of Life
Quality of life measures were not included in this study, but distinct differences were observed between CaR and APS-1 groups. Most patients with CaR did well academically; patients F, G, H, I, and M were among the top students in their class, and all went to college. Patients with APS-1 did not attain the academic level of patients with CaR. Multiple comorbidities led to poor attendance at school; patients B, C, and D had extended home schooling. Patients with APS-1 reported more fatigue, especially those with Addison disease, a symptom, however, which has also been reported in adults with hypoparathyroidism. 27 
Discussion
In up to a decade of observational study in 14 children with severe genetic hypoparathyroidism, we have shown that PTH 1-34 given by twice-or thrice-daily subcutaneous injection is safe and effective, with normal linear growth, bone accrual, and kidney function, and normal or slightly below normal serum calcium values in nearly all measurements. Twenty-four hour urine calcium excretion was normal in only 40% of values at baseline on conventional therapy. During PTH therapy, 76% of urine calcium in APS-1 and 48% of urine calcium measurements in patients with CaR were within normal limits. Nephrocalcinosis was present at baseline in all patients who had imaging and progressed in 5 of 12 patients (2 with APS-1 and 3 with CaR) who underwent repeated renal imaging, which highlights the difficulty in normalizing calcium homeostasis with twice-daily or thrice-daily PTH 1-34 injections. This observed progression in nephrocalcinosis, however, was not accompanied by a decrease in renal function. PTH 1-34 dose requirements during this study were consistent with prior studies, which have shown that treatment of genetic hypoparathyroidism requires higher PTH 1-34 dosage, whether administered twice-daily or by pump, compared with treatment of postsurgical hypoparathyroidism. 5, 14, 15 During the first 2 years of PTH 1-34 treatment, a transient reduction in bone accretion rate was observed at the distal radius. This skeletal area is comprised mostly of cortical bone, which exhibits decreased bone density in adults with PTH excess. 28 Future studies with peripheral quantitative computed tomography, a measure of volumetric BMD, may permit distinction between cortical vs trabecular bone effects and provide a greater understanding of the effects of PTH 1-34 in children with hypoparathyroid who, unlike adults with hypoparathyroidism, 29 have normal bone turnover and do not manifest high cortical bone density. From a clinical perspective, the subsequent normal trajectory of bone accrual, at all observed sites, and to adult height in most subjects, is reassuring.
A serum Ca × P <55 mg ) has been advocated to lower risk of renal calcification in adults with hypoparathyroidism and risk of arterial calcification in chronic kidney disease. 2, 25, 26 However, because variable serum phosphate levels primarily determine the Ca × P, Uhlig et al have advised against using the Ca × P for decision-making in renal insufficiency. 30 Further, the Ca × P has not proven to be a better predictor than blood and urine calcium for renal calcification, 31 and has not been used in pediatric hypoparathyroidism management in this or other studies. The current study showed no correlation between the morning pre-PTH 1-34 dose Ca × P value and 24-hour urine calcium-some of the highest urine calcium levels were associated with the lowest Ca × P value, and >90% of Ca × P values were <55 mg 2 /dL 2 , despite persisting hypercalciuria in 24% (APS-1) to 52% (CaR) of urine calcium measurements.
Rodent PTH carcinogenicity studies indicating dosedependent osteogenic sarcoma has led to black box warnings for both currently marketed forms of PTH (Forteo [rhPTH1-34] and Natpara [rhPTH1-84]). 32 Although no increased osteosarcoma risk has appeared during 15 years of rhPTH 1-34 use in >500 000 patients with osteoporosis, the toxicology data and black box warning remain a continuing concern and an obstacle to pediatric use outside of research settings. Nonetheless, such research is needed because, in severe pediatric hypoparathyroidism, recurrent emergency department visits, tetany, seizures, and renal damage remain an ongoing problem with conventional treatment. Although pediatric exposure to PTH 1-34 remains limited (96 patient-years in the current study and 217 patient-years for all studies from Winer et al, including several who were followed into early adulthood), to our knowledge there have been no cases of osteosarcoma during pediatric use by our group or others.
Despite the overall long-term safety and efficacy of PTH 1-34 in this study, multiple PTH injections are pharmacologic, not physiologic, replacement. In short-term studies, we have shown that continuous delivery by insulin pump produces more physiologic calcium profiles in blood and urine, reduces markers of bone turnover and the need for magnesium supplementation, and substantially reduces the overall PTH 1-34 dose requirement. 14, 15 We hypothesize that such an approach will represent a further advance toward the goal of truly physiologic replacement.
The progression of nephrocalcinosis observed in 5 of our patients had at least 2 potential causes-the cumulative effect of IV calcium administration during emergency department visits for tetany (or for malabsorption or adrenal insufficiency in patients with APS-1), and the unphysiologic nature of intermittent PTH 1-34 replacement by multiple daily injection. Early evidence suggests that the second of these causes may be improved by pump delivery. To address the problem of intermittent hypo-or hypercalcemia, however, a selfmeasured blood calcium device, analogous to the self-measured blood glucose devices for diabetes, is an urgent unmet need. Such a device could permit frequent dose adjustment, reduce overtreatment, and reduce IV calcium administration during emergency department visits for tetany or seizure.
In conclusion, PTH 1-34 administered twice or thrice daily represents a safe and effective long-term therapy for children with severe hypoparathyroidism because of APS-1 or CaR. ■ 
